TriSalus Life Sciences, Inc.
For the period ended Dec 31, 2025. Filed Mar 5, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 5, 2026
TLSI$3.22-0.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statement of Operations
Consolidated Statements of Operations
(in thousands, except share and per share data)
| Years Ended | ||
|---|---|---|
| December 31, 2025 | December 31, 2024 | |
| Revenue | $45,151 | $29,431 |
| Cost of goods sold | 6,965 | 4,103 |
| Gross profit | 38,186 | 25,328 |
| Operating expenses: | ||
| Research and development | 14,965 | 17,688 |
| Sales and marketing | 28,709 | 25,839 |
| General and administrative | 21,458 | 17,966 |
| Loss from operations | (26,946) | (36,165) |
| Other income (expense) | ||
| Interest income | 555 | 404 |
| Interest expense | (5,544) | (3,090) |
| Change in fair value of SEPA, warrant and revenue base redemption liabilities | (4,086) | (2,107) |
| Change in fair value of contingent earnout liability | (2,743) | 11,231 |
| Other expense, net | (456) | (312) |
| Loss before income taxes | (39,220) | (30,039) |
| Income tax expense | (7) | (6) |
| Net loss | $(39,227) | $(30,045) |
| Series A Preferred Stock conversion inducement | $(18,516) | $— |
| Deemed dividend related to Series A Preferred Stock conversion | (11,947) | — |
| Undeclared dividends on Series A Preferred Stock | — | (3,188) |
| Net loss attributable to common stockholders | $(69,690) | $(33,233) |
| Net loss per common share, basic and diluted | $(1.84) | $(1.31) |
| Weighted average common shares outstanding, basic and diluted | 37,897,785 | 25,331,753 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.